136 related articles for article (PubMed ID: 18609486)
1. Vigabatrin-induced visual dysfunction in Chinese patients with refractory epilepsy.
Hui AC; Liu DT; Wong KK; Man BL; Leung T; Lam PT; Lam DS
Eur J Ophthalmol; 2008; 18(4):624-7. PubMed ID: 18609486
[TBL] [Abstract][Full Text] [Related]
2. Visual field defects in patients taking vigabatrin.
Midelfart A; Midelfart E; Brodtkorb E
Acta Ophthalmol Scand; 2000 Oct; 78(5):580-4. PubMed ID: 11037919
[TBL] [Abstract][Full Text] [Related]
3. A controlled study of vigabatrin and visual abnormalities.
Manuchehri K; Goodman S; Siviter L; Nightingale S
Br J Ophthalmol; 2000 May; 84(5):499-505. PubMed ID: 10781514
[TBL] [Abstract][Full Text] [Related]
4. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.
Sergott RC; Johnson CA; Laxer KD; Wechsler RT; Cherny K; Whittle J; Feng G; Lee D; Isojarvi J
Epilepsia; 2016 Oct; 57(10):1634-1642. PubMed ID: 27580566
[TBL] [Abstract][Full Text] [Related]
5. Visual field defects associated with vigabatrin therapy.
Lawden MC; Eke T; Degg C; Harding GF; Wild JM
J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):716-22. PubMed ID: 10567485
[TBL] [Abstract][Full Text] [Related]
6. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making.
Paul SR; Krauss GL; Miller NR; Medura MT; Miller TA; Johnson MA
Epilepsia; 2001 Apr; 42(4):525-30. PubMed ID: 11440348
[TBL] [Abstract][Full Text] [Related]
7. Binasal visual field defects are not specific to vigabatrin.
Gonzalez P; Sills GJ; Parks S; Kelly K; Stephen LJ; Keating D; Dutton GN; Brodie MJ
Epilepsy Behav; 2009 Nov; 16(3):521-6. PubMed ID: 19815465
[TBL] [Abstract][Full Text] [Related]
8. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
Newman WD; Tocher K; Acheson JF
Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
[TBL] [Abstract][Full Text] [Related]
9. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication.
Hardus P; Verduin WM; Postma G; Stilma JS; Berendschot TT; van Veelen CW
Epilepsia; 2000 May; 41(5):581-7. PubMed ID: 10802764
[TBL] [Abstract][Full Text] [Related]
10. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.
Wild JM; Chiron C; Ahn H; Baulac M; Bursztyn J; Gandolfo E; Goldberg I; Goñi FJ; Mercier F; Nordmann JP; Safran AB; Schiefer U; Perucca E
CNS Drugs; 2009 Nov; 23(11):965-82. PubMed ID: 19845417
[TBL] [Abstract][Full Text] [Related]
11. Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.
Fledelius HC
Acta Ophthalmol Scand; 2003 Feb; 81(1):41-6. PubMed ID: 12631018
[TBL] [Abstract][Full Text] [Related]
12. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
Lawthom C; Smith PE; Wild JM
Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
[TBL] [Abstract][Full Text] [Related]
13. The Topographical Relationship between Visual Field Loss and Peripapillary Retinal Nerve Fibre Layer Thinning Arising from Long-Term Exposure to Vigabatrin.
Wild JM; Aljarudi S; Smith PEM; Knupp C
CNS Drugs; 2019 Feb; 33(2):161-173. PubMed ID: 30637668
[TBL] [Abstract][Full Text] [Related]
14. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
[TBL] [Abstract][Full Text] [Related]
15. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.
Ponjavic V; Andréasson S
Doc Ophthalmol; 2001 Jan; 102(1):63-72. PubMed ID: 11475366
[TBL] [Abstract][Full Text] [Related]
16. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
[TBL] [Abstract][Full Text] [Related]
17. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
Sergott RC; Bittman RM; Christen EM; Sagar SM
Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
Daneshvar H; Racette L; Coupland SG; Kertes PJ; Guberman A; Zackon D
Ophthalmology; 1999 Sep; 106(9):1792-8. PubMed ID: 10485552
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication.
Kjellström U; Andréasson S; Ponjavic V
Acta Ophthalmol; 2014 Mar; 92(2):149-57. PubMed ID: 23387307
[TBL] [Abstract][Full Text] [Related]
20. Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship.
Frisén L
Acta Ophthalmol Scand; 2004 Feb; 82(1):54-8. PubMed ID: 14738486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
